MoonLake Immunotherapeutics (MLTX) Competitors

$18.19 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$18.15 -0.04 (-0.24%)

As of 05/22/2026 07:44 PM Eastern

MLTX vs. CRSP, INDV, MANE, NNNN, and KNSA

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MarketBeat compares MoonLake Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MoonLake Immunotherapeutics include CRISPR Therapeutics (CRSP), Indivior (INDV), MANE (MANE), Anbio Biotechnology (NNNN), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "pharmaceutical products" industry.

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

In the previous week, CRISPR Therapeutics had 6 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 11 mentions for CRISPR Therapeutics and 5 mentions for MoonLake Immunotherapeutics. CRISPR Therapeutics' average media sentiment score of 1.28 beat MoonLake Immunotherapeutics' score of 1.01 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,383.82	-$581.60M	-$6.22	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CRISPR Therapeutics currently has a consensus price target of $65.47, suggesting a potential upside of 30.01%. MoonLake Immunotherapeutics has a consensus price target of $23.85, suggesting a potential upside of 31.09%. Given MoonLake Immunotherapeutics' higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Summary

CRISPR Therapeutics beats MoonLake Immunotherapeutics on 9 of the 16 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Indivior?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Indivior. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 4 mentions for Indivior. MoonLake Immunotherapeutics' average media sentiment score of 1.01 beat Indivior's score of 0.17 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Indivior has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Indivior has a net margin of 19.44% compared to MoonLake Immunotherapeutics' net margin of 0.00%. MoonLake Immunotherapeutics' return on equity of -85.15% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Indivior	19.44%	-219.26%	29.40%

Indivior has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Indivior	$1.24B	3.69	$210M	$1.95	19.25

MoonLake Immunotherapeutics presently has a consensus price target of $23.85, indicating a potential upside of 31.09%. Indivior has a consensus price target of $39.33, indicating a potential upside of 4.81%. Given MoonLake Immunotherapeutics' higher probable upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

MoonLake Immunotherapeutics and Indivior tied by winning 8 of the 16 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to MANE?

MANE (NYSE:MANE) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than MANE. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 3 mentions for MANE. MoonLake Immunotherapeutics' average media sentiment score of 1.01 beat MANE's score of 0.46 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MANE currently has a consensus target price of $100.00, suggesting a potential downside of 1.40%. MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 31.09%. Given MoonLake Immunotherapeutics' higher possible upside, analysts clearly believe MoonLake Immunotherapeutics is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

MANE's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Summary

MoonLake Immunotherapeutics beats MANE on 6 of the 9 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Anbio Biotechnology?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

MoonLake Immunotherapeutics currently has a consensus target price of $23.85, indicating a potential upside of 31.09%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

MoonLake Immunotherapeutics has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.71, meaning that its stock price is 371% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 1 mentions for Anbio Biotechnology. MoonLake Immunotherapeutics' average media sentiment score of 1.01 beat Anbio Biotechnology's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anbio Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anbio Biotechnology's return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Anbio Biotechnology	N/A	N/A	N/A

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Anbio Biotechnology has higher revenue and earnings than MoonLake Immunotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Anbio Biotechnology	$8.65M	540.96	$6.40M	N/A	N/A

Summary

MoonLake Immunotherapeutics beats Anbio Biotechnology on 7 of the 12 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Kiniksa Pharmaceuticals International had 1 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 5 mentions for MoonLake Immunotherapeutics. Kiniksa Pharmaceuticals International's average media sentiment score of 1.25 beat MoonLake Immunotherapeutics' score of 1.01 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, indicating a potential upside of 14.31%. MoonLake Immunotherapeutics has a consensus target price of $23.85, indicating a potential upside of 31.09%. Given MoonLake Immunotherapeutics' higher probable upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

Kiniksa Pharmaceuticals International has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	6.05	$59.01M	$0.90	59.16
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Summary

Kiniksa Pharmaceuticals International beats MoonLake Immunotherapeutics on 11 of the 15 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.30B	$3.37B	$6.45B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-4.70	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	5.14	7.09	10.37	7.14
Net Income	-$227.32M	$24.45M	$3.57B	$335.98M
7 Day Performance	10.64%	5.45%	6.01%	3.56%
1 Month Performance	5.88%	2.43%	3.52%	2.54%
1 Year Performance	-53.28%	62.98%	34.13%	35.05%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	3.9067 of 5 stars	$18.19 flat	$23.85 +31.1%	-53.3%	$1.30B	N/A	N/A	2	Positive News
CRSP CRISPR Therapeutics	3.5727 of 5 stars	$47.82 -1.5%	$65.47 +36.9%	+36.6%	$4.60B	$3.51M	N/A	460
INDV Indivior	3.5155 of 5 stars	$36.93 +1.1%	$39.33 +6.5%	+233.3%	$4.47B	$1.29B	18.82	1,051
MANE MANE	N/A	$101.83 +1.4%	$100.00 -1.8%	N/A	$4.22B	N/A	N/A	19
NNNN Anbio Biotechnology	0.9263 of 5 stars	$29.04 +3.2%	N/A	N/A	$4.18B	$8.65M	N/A	27	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. CRSP, INDV, MANE, NNNN, and KNSA

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Indivior?

Summary

How does MoonLake Immunotherapeutics compare to MANE?

Summary

How does MoonLake Immunotherapeutics compare to Anbio Biotechnology?

Summary

How does MoonLake Immunotherapeutics compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. CRSP, INDV, MANE, NNNN, and KNSA

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

Is CRSP or MLTX more profitable?

Does the media prefer CRSP or MLTX?

Which has better earnings & valuation, CRSP or MLTX?

Do insiders and institutionals have more ownership in CRSP or MLTX?

Do analysts recommend CRSP or MLTX?

Which has more risk and volatility, CRSP or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Indivior?

Does the media refer more to MLTX or INDV?

Do institutionals and insiders believe in MLTX or INDV?

Which has more volatility & risk, MLTX or INDV?

Is MLTX or INDV more profitable?

Which has higher earnings and valuation, MLTX or INDV?

Do analysts recommend MLTX or INDV?

Summary

How does MoonLake Immunotherapeutics compare to MANE?

Do institutionals and insiders hold more shares of MANE or MLTX?

Does the media prefer MANE or MLTX?

Do analysts recommend MANE or MLTX?

Is MANE or MLTX more profitable?

Which has preferable earnings & valuation, MANE or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Anbio Biotechnology?

Do analysts recommend MLTX or NNNN?

Which has more volatility & risk, MLTX or NNNN?

Does the media refer more to MLTX or NNNN?

Is MLTX or NNNN more profitable?

Do insiders and institutionals believe in MLTX or NNNN?

Which has higher earnings and valuation, MLTX or NNNN?

Summary

How does MoonLake Immunotherapeutics compare to Kiniksa Pharmaceuticals International?

Does the media favor KNSA or MLTX?

Is KNSA or MLTX more profitable?

Do analysts rate KNSA or MLTX?

Which has more volatility and risk, KNSA or MLTX?

Do insiders and institutionals believe in KNSA or MLTX?

Which has higher valuation and earnings, KNSA or MLTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools